GleamWall
中文EN

GILD GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882095 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.5%
TTM net income YoY-147.6%
TTM EPS YoY-148.5%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR—

Margins

Gross margin79.9%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
EBITDA margin-6.3%

Returns

ROE-22.3%
ROA-7.0%
ROIC (approx.)-5.2%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity2.01x
Current ratio1.38x
Interest coverage-2.34x

Cash quality & payout

Operating cash flow / net income-3.75x
Accruals ratio-33.4%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$29.44B$28.75B$27.12B$27.28B$27.30B
Cost of revenue$6.23B$6.25B$6.50B$5.66B$6.60B
Gross profit$23.21B$22.50B$20.62B$21.62B$20.70B
R&D expense$5.80B$5.91B$5.72B$4.98B$4.60B
SG&A expense$5.77B$6.09B$6.09B$5.67B$5.25B
Operating income$10.02B$1.66B$7.61B$7.33B$9.92B
Interest expense$1.02B$977.00M$944.00M$935.00M$1.00B
Pretax income$9.80B$690.00M$6.86B$5.81B$8.28B
Income tax$1.29B$211.00M$1.25B$1.25B$2.08B
Net income$8.51B$480.00M$5.67B$4.59B$6.22B
EBITDA$10.39B$2.04B$7.96B$7.65B$10.25B
EPS (basic)6.840.384.543.664.96
EPS (diluted)6.780.384.503.644.93
Dividends declared per share3.163.083.002.922.84
Weighted avg. shares (diluted)1.25B1.25B1.26B1.26B1.26B
Balance sheet
Cash & equivalents$7.56B$9.99B$6.08B$5.41B$5.34B
Short-term investments$68.00M$0$1.18B$973.00M$1.18B
Receivables$4.91B$4.42B$4.66B$4.78B$4.49B
Inventory$1.77B$1.71B$1.79B$1.51B$1.62B
Current assets$18.34B$19.17B$16.09B$14.44B$14.77B
PP&E, net$5.61B$5.41B$5.32B$5.47B$5.12B
Goodwill$8.31B$8.31B$8.31B$8.31B$8.33B
Intangibles$16.98B$19.95B$26.45B$28.89B$33.45B
Total assets$59.02B$58.99B$62.12B$63.17B$67.95B
Current liabilities$11.81B$12.00B$11.28B$11.24B$11.61B
Short-term debt$2.81B$1.81B$1.80B$2.27B$1.52B
Long-term debt$22.13B$24.90B$23.19B$22.96B$25.18B
Total debt$24.94B$26.71B$24.99B$25.23B$26.70B
Total liabilities$36.41B$39.75B$39.38B$41.96B$46.89B
Shareholders' equity$22.70B$19.33B$22.83B$21.24B$21.07B
Net debt$17.37B$16.72B$18.90B$19.82B$21.36B
Shares outstanding1.24B1.25B1.25B1.25B1.25B
Cash flow statement
Operating cash flow$10.02B$10.83B$8.01B$9.07B$11.38B
Capital expenditure$563.00M$523.00M$585.00M$728.00M$579.00M
Free cash flow$9.46B$10.30B$7.42B$8.34B$10.80B
Investing cash flow-$4.79B-$3.45B-$2.27B-$2.47B-$3.13B
Financing cash flow-$7.75B-$3.43B-$5.12B-$6.47B-$8.88B
Depreciation & amortization$370.00M$381.00M$354.00M$323.00M$329.00M
Stock-based compensation$894.00M$835.00M$766.00M$637.00M$635.00M
Dividends paid$4.00B$3.92B$3.81B$3.71B$3.60B
Share buybacks$1.92B$1.15B$1.00B$1.40B$546.00M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.